PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate at two upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com. TD Cowen 44th Annual Health Care Conference Presenters: Daphne Zohar, Founder and Chief E.

PureTech to Present at Two Upcoming Investor Conferences

Akili Inc

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of A.

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

PureTech Health PLC Sponsored ADR (PRTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround

Karuna Therapeutics Inc

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) ("Karuna") announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of Septembe.

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

PureTech Health plc – Half-Year Report

argenx

Pfizer

After recovering from COVID-19 infections, many people enter an extended period during which they suffer from a catalog of additional serious symptoms. It is estimated that at least 65 million people continue to experience long COVID.

This Emerging Market Could Be the Next Big Thing in Biotech

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2022.

PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC announced a lucrative royalty deal with Royalty Pharma for its KarXT drug, developed by Karuna Therapeutics. In response, Liberum, the corporate broker, has increased its target price for PureTech Health from 420p to 470p, reiterating its 'buy' recommendation.

PureTech Health remains undervalued after KarXCT deal, says broker

Shares in PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC jumped 10% after it agreed a US$500mln royalty deal, US$100mln of which will be paid upfront. In the first half hour of trading the shares were up 21.49p at  224.49p.

PureTech Health shares jump 10% on US$500mln royalty deal

Royalty Pharma

Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, in conjunction with the Massachusetts General Hospital (MGH) Frontotemporal Disorders (FTD) Unit, has been selected by the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging &

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer and Eric Elenko, Chief Innovation Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 10:40am EST. A webcast of the presentation will be available at https://investors.puretechhealth.com.

PureTech to Present at the SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences:

Vedanta Biosciences to Present at Upcoming Investor Conferences

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022.

PureTech Provides End of Year Report on Key Progress

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced topline results from the completed, multi-part Phase 1 trial of LYT-300 (oral allopregnanolone).

PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. PST / 5:15 p.m. EST. A webcast of the presentation will be available at https://investors.puretechhealth.com.

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today shared new data supporting the clinical potential of LYT-200, a fully human monoclonal antibody (mAb) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia. The data were shared in a scientific poster presented at the American Society of Hematology (ASH) 64th Annual Meeting. LYT-200 is a therapeutic candidate targeting galectin-9, which is expressed by tumors and immune cells and plays a key role in cancer treatment resistance. It is also in development as a treatment for a range of cancer indications with otherwise poor survival rates.

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, announced it has raised a $19.25 million Series B investment round with a strong group of financial and strategic investors.

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring

BOSTON--( BUSINESS WIRE )--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech's Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023.

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech's Glyph™ Platform

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D.

PureTech to Present at the Jefferies London Healthcare Conference

Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

Nektar Therapeutics

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC and Nektar Therapeutics (NASDAQ:NKTR) said they have mutually agreed to terminate discussions regarding a possible combination of the two companies.  The talks were first announced on 7 October 2022 in response to press speculation.

PureTech Health and Nektar Therapeutics end tie-up talks

OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Form 8 (OPD) PureTech Health PLC

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR), Inc.  Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible combination, which may include an offer for the share capital of PureTech.  “PureTech and Nektar remain in discussions regarding the proposal.

News for PureTech Health PLC Stock (PRTC)